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Abstract
The AID/APOBEC family (activation induced deaminase/apolipoprotein B mRNA editing cytokine deaminase) in B cells play
important roles in adaptive and innate immunity. Whereas APOBEC3G has been studied in CD4+ T cells and myeloid cells its
functional potential in B cells has received little attention. AID combines two critical functions of antibodies, class switching
and affinity maturation and may serve as a functional surrogate of protection. These functions were studied following
systemic immunization of rhesus macaques with recombinant HLA constructs, linked with HIV and SIV antigens and HSP70
to dextran. The results showed significant upregulation of AID in CD20+ B cells, APOBEC 3G in CD27+ memory B cells and
CD4+ effector memory T cells. After immunization the upregulated APOBEC 3G and AID were directly correlated in B cells
(p,0.0001). Following challenge with SHIV SF162.P4 the viral load was inversely correlated with AID in B cells and APOBEC
3G in B and T cells, suggesting that both deaminases may have protective functions. Investigation of major interactions
between DC, T cells and B cells showed significant increase in membrane associated IL-15 in DC and CD40L in CD4+ T cells.
IL-15 binds the IL-15 receptor complex in CD4+ T and B cells, which may reactivate the DC, T and B cell interactions. The
overall results are consistent with AID inhibiting pre-entry SHIV by eliciting IgG and IgA antibodies, whereas APOBEC 3G
may contribute to the post-entry control of SHIV replication and cellular spread.
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Introduction
B cells do not express primary CD4 and CCR5 or CXCR4
coreceptors for HIV-1 binding and the virus does not replicate
productively, unlike in CD4+ T cells. However, there is ample
evidence that B cells can bind HIV-1 gp120 via surface Ig (VH3)
[1], HIV-1 bound complement and its CR2 receptor (CD21) [2]
or immune complexes of HIV-1 antibody with complement [3].
These surface-bound HIV-1 do not replicate unlike with DC-
SIGN, also expressed by B cells, which may bind and internalize
the virus and undergo low level replication [4]. These methods of
HIV-1-bound B cells may result in trans infection of CD4+ T cells,
though the mechanism of transmission has not been elucidated.
Cell to cell contact between B cells and activated CD4+ T cells
may be required, as has been suggested between follicular DC and
CD4+ T cells in lymphoid tissue [5,6].
B cells express two major deaminases, AID [7–9] and
APOBEC3G (A3G) [10–13], which exert their functions by
deaminating deoxycitidine to deoxyuridine. AID initiates somatic
hypermutation (SHM), which generates high affinity antibodies by
a process of affinity maturation [7–9]. AID also elicits class switch
recombination (CSR) of antibody isotypes from IgM to IgG, IgA
and IgE [14]. A3G is an intracellular viral restricting factor, which
induces lethal hypermutation or acts by a non-editing mechanism
[10–13]. Recent investigations have demonstrated that A3G is
upregulated following mucosal immunization with SIV antigens
and CCR5 peptides linked to the 70 kDa heat shock protein and is
maintained for over 17 weeks [15]. The longevity of A3G mRNA
and protein were associated with CD4+CCR5+ memory T cells in
circulating PBMC, iliac lymph nodes and rectal cells of the
immunized compared with unimmunized macaques. Further-
more, a significant increase in A3G mRNA in the CD4+CCR5+
circulating cells and the draining iliac lymph node cells was found
following mucosal challenge with SIVmac251 in the immunized
uninfected macaques, consistent with a protective effect exerted by
A3G [15]. In another macaque study a combined mucosal
adjuvant consisting of TLR agonists and IL-15, with peptides and
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boosted with MVA expressing SIV proteins also elicited long-lived
A3G [16]. As with the previous investigation A3G expression was
correlated with protection against rectal mucosal challenges with
SIV mac251. Whereas A3G is an innate virus restricting factor,
AID is involved mostly in adaptive immunity eliciting IgG and IgA
antibody class switch and affinity maturation which may inhibit
HIV and other retroviral infections.
These two deaminases do not seem to have been studied in vivo
and we have explored their combined effects in HLA immunized
macaques. Xenogeneic or allogeneic immunity is one of the most
potent natural immune responses, MHC polymorphism plays a
critical role in HIV control [17] and can elicit protection in
immunized macaques [18–22] and humans [23]. Furthermore,
allo-immunization induces CD40L expression in CD4+ T cells
[24] and may activate phosphorylation of IkB kinase complex,
followed by nuclear translocation of NF-kB, which generates AID
and induces CSR in B cells by binding to kB sites on IH promoters
[25,26]. CD40L bound to CD40 in DC activates ERK 1/2 and
p38 MAP kinase and induces A3G expression [27]. Allogeneic
stimulation in vitro and in vivo in humans also upregulates A3G
mRNA in CD4+ T cells [28].
In this study immunization of rhesus macaques with HLA class I
and II, trimeric HIV gp140, SIVp27, HSP70 and an adjuvant
upregulated A3G in both CD4+ T cells and CD20+ B cells and the
corresponding memory cells. AID was also upregulated in CD20+
B cells, which showed significant direct correlation with A3G in B
cells. As both AID and A3G can be upregulated by immunization
with the HLA constructs, we investigated their potential
involvement in B and T cell protection against a SHIV challenge.
An inverse correlation was recorded between the viral load and
A3G, as well as AID in B cells in addition to A3G in CD4+ T cells.
These findings are consistent with a dual function of immunization
with the combined HLA-HIV/SIV vaccine, eliciting both innate
and adaptive immunity, involving T and B cells and preventing or
controlling SHIV replication and transmission.
Results
Immunization schedule and the effect on SHIV SF162.P4
challenge
Previous investigation of this series [29] demonstrated total
prevention of SHIVSF162 infection in 2/8 macaques and
significant decrease in viral load in the remaining 6 animals in
group 3 (p,0.05), which were immunized with all vaccine
components – recombinant HLA-class I and II, trimeric
HIVgp140, SIVp27, HSP70 and the TiterMax adjuvant and
challenged by IV SHIV SF162.P4. Macaques in the other three
immunized groups had received all vaccine components, except
SHIV in group 1, HLA I and II in group 2 and the adjuvant in
group 4 (Table 1). All animals in the remaining immunized groups
1, 2 and 4, as well as the unimmunized group 5 were infected and
showed no decrease in viral load. The 3 immunized groups had
received all vaccine components, except for SHIV in group 1,
HLA I and II in group 2 and the adjuvant in group 4 (Table 1).
Upregulation of A3G expression in B cells
The innate anti-viral factor A3G was studied in PBMC B cells of
the 5 groups of macaques before and after the 4th (final)
immunization by flow cytometry. A3G in CD20+CD27+ memory
B cells was increased significantly only in group 3 macaques
(p,0.05; Fig 1B, C). Although A3G in CD20+ B cells was also
upregulated, this reached significant levels after the 2nd (Fig 2B,D)
but not after the last immunization (Fig 1A). These results suggest
that increased A3G expression was maintained only in
CD20+CD27+ memory B cells and appears to be limited to group
3 immunized and protected macaques, which is consistent with
previous long-term persistence of A3G in CD4+ memory T
cells[15,16].
Upregulation of AID in B cells
To study the effect of immunization on the expression of AID in
CD20+ B cells we examined first the baseline proportion of AID in
B cells, which varied between 0.4–17.4% (mean6sem: 5.460.7%)
in the macaques. An increase in AID was found after the first
immunization, which reached significant levels after the second
immunization in the 3 groups immunized with the adjuvant
(Fig. 2A, C). Interestingly, group 1 immunized with HLA class I
and II (but not HIVgp120) showed an increase in AID, the
significance of which was higher (p = 0.025) than in group 2
immunized with HIV gp120 (but not HLA) (p = 0.043), however,
group 3 immunized with both HLA and HIV antigens the
significance increased further (p = 0.003), suggesting a partly
additive function (Fig 2A, C). Both AID and A3G are produced
in B cells, with a comparable pattern of responses to the 3 types of
vaccines (groups 1, 2 and 3; Fig. 2A, B). Indeed, a very significant
correlation was found between AID and A3G expression in
CD20+ B cells in the combined immunized groups of macaques
(p = 0.0015, Fig 2C) and a small proportion of B cells express both
AID and A3G (Fig. 2D).
A3G mRNA in PBMC and protein expression in CD4+ T
cells
A significant increase in A3G mRNA assayed by RT-PCR was
found in PBMC after the last immunization only in the protected
group 3 animals (p = 0.046), none in group 2 and limited increase
in groups 1 and 4 (Fig. 3A). The pre-immunization mRNA was
99(628), which increased post-immunization over 2-fold to 236
(685). A3G protein was then studied by flow cytometry in CD4+
memory T cells, which showed increased A3G expression in both
CCR7+ central and CCR72 effector memory T cells in all 4
immunized, except the former in group 3 macaques (Fig. 3B, C
and representative profiles in D, E). It should be noted that in
addition to A3G, A3F and to a lesser extent A3B are also capable
of retroviral cDNA cytosine deamination [30] but these have not
Table 1. Vaccine constituents used for immunization in 4
groups of 8 rhesus macaques per group of rhesus macaques
at 0, 4, 8 and 16 weeks administered by the SC route in all
except group 4 IM, group 5 was unimmunized.
Vaccine component Adjuvant
Group
HLA
class I
HLA
class II
HIVgp
140 SIVp27 HSP70
Titer
Max
1 + + 2 2 + +
2 2 2 + + + +
3 + + + + + +
4 + + + + + 2
5 2 2 2 2 2 2
Animals in group 1 consisted of 8 animals (except group 4 had 6 animals)
challenged with SHIVSF162.P4 grown in C8166-CCR5+ T cells (HLA*A01, DR*04).
All vaccine components were biotinylated, linked to streptavidin-bound
dextran and formulated into an emulsion with the TiterMax adjuvant (except
group 4 and 5).
doi:10.1371/journal.pone.0034433.t001
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been studied due to limitations of PBMC required for the entire
investigation.
Comparative analysis of A3G expression between CD4+
CCR72 effector memory T cells and CD20+CD27+
memory B cells
We explored the possibility that immunization with the HLA
construct and SHIV may have elicited concomitant enhancement
of A3G in CD4+ T and B cells. Indeed, A3G expression in CD4+
effector memory T cells (CD95+CCR72) was directly correlated
with CD20+CD27+ memory B cells (p = 0.045) in the whole cohort
of animals (Fig. 4A). This result was replicated in the protected
group 3 (p = 0.046), in contrast to the unprotected group 1 cohort
(p = 0.537; Fig. 4C and B). These results are consistent with the
concept that HLA immunization elicited parallel upregulation of
A3G expression in subsets of memory CD4+ T cells and CD20+ B
cells.
Correlation between A3G mRNA in PBMC, A3G
expression in CD20+ or CD27+ B cells and HLA,
neutralizing antibodies
A potential relationship between A3G and anti-HLA or
neutralizing antibodies was then explored, as HLA immunization
may upregulate both A3G and AID deaminases in B cells.
Significant direct correlation was found between A3G mRNA and
both HLA-I (p = 0.033) and HLA-II antibodies (p = 0.004; Fig. 4D,
G). Evaluation of the separate groups showed a significant direct
correlation only in group 3 protected animals between A3G
Figure 1. A3G in CD20+ and CD27+ memory B cells pre- and post-immunization in the 4 groups. Expression of A3G in (A) CD20+ B cells
and (B) CD20+CD27+ memory B cells in 5 groups of macaques before and after the 4th immunization assayed by flow cytometry with MAb to A3G,
CD20 and CD27 and (C) representative illustration; (n = 8 per group, except gp4 n= 6). * p,0.05. In all figures the 2 uninfected macaques in group 3
are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g001
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mRNA and anti-HLA II (DR) antibodies (p = 0.046; Fig. 4 I), and
a trend of correlation between neutralizing activity and A3G
mRNA, which failed to reach significance (r = 0.619; Fig. 4L).
Correlation between AID expression in B cells and HLA-
class I and II, and HIVgp120 antibodies
Expression of AID in CD20 B cells was also examined in
relation to HLA class I and II antibodies. There was no
correlation between AID expression in the immunized groups 1–
4 and HLA-I or II antibodies (Fig. S1A, B). Examination of the
separate groups, however showed a direct trend of correlation with
HLA-II antibodies only in group 3 protected animals, which
however does not reach significance (r = 0.61, p = 0.11; Fig. S1F).
CSR is another functional activity of AID which was examined for
HIVgp120 IgM, IgG and IgA antibodies. As expected only IgM to
HIVgp120 was significantly upregulated after the first immuniza-
tion, whereas IgG and IgA antibodies were upregulated only after
the 4th immunization (Fig. S2 A–F). Furthermore, direct correla-
tion was observed between AID in CD20+ B cells, both with IgG
and IgA antibodies to HIVgp120 in the combined groups
(Fig. S2G, H), and high coefficient correlation (r = 0.62), though
not significant between IgA and AID in group 3 (Fig. S2 I–J).
Correlation between A3G expression in PBMC, CD4+ T
cells, or AID in B cells and the viral load
We have then explored the critical question of correlates of
protection following IV challenge with heterologous
SHIVSF162.P4. A3G mRNA in PBMC showed very significant
inverse correlation with the peak viral load (PVL, p,0.0001) and
cumulative viral load (CVL, p,0.0001) in the entire series of
animals (Fig. 5A, B). AID in CD20+ B cells also showed a
significant inverse correlation both with PVL (p = 0.012) and CVL
(p = 0.031) (Fig. 5C, D), as did A3G in CD20+ B cells with CVL
(p = 0.046) and likely with PVL (p = 0.052) (Fig. 5E, F). A3G in
CD20+ CD27+ memory B cells showed only a strong inverse trend
with CVL (p = 0.07), but not with PVL (Fig. S3B, A). A3G protein
Figure 2. AID and A3G expression in CD20+ B cells pre- and post-2nd immunization and their correlation. Comparative investigation of
(A) AID and (B) A3G expression in CD20+ B cells before and after the 2nd immunization in the 4 groups of immunized macaques; group 5
unimmunized controls remained unchanged (data not presented). Correlation between A3G and AID expression in CD20+ B cells in the 5 groups after
2nd immunization is presented in (C). Representative flow cytometry of AID and A3G in pre- and post 2nd immunization is shown in (D). * p,0.05 and
** p,0.01. In all figures the 2 uninfected macaques in group 3 are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g002
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in CD4+ T cells was also significantly inversely correlated between
the effector memory CD4+ T cells (CD95+CCR72) and CVL
(p = 0.01, Fig. 5H) and to a lesser extent with the PVL (p = 0.061,
Fig. 5G). However, the central memory CD4+ T cells
(CD95+CCR7+) failed to show any correlation (Fig. S3C, D).
Altogether, A3G in both CD4+ T cells and B cells and AID in B
cells demonstrated significant inverse correlation with the viral
load, suggesting that A3G and AID in these cells may contribute to
inhibition of viral replication.
Expression of IL-15 in DC and CD40L in CD4+ T cells
Allogeneic stimulation of CD4+ T cells in vitro induces CD40L
[24], with significant increase in A3G mRNA [28]. Interaction
between CD40L in CD4+ T cells and CD40 in DC activates
transcription of membrane associated (ma) IL-15/IL-15Ra
molecules in DC in vitro [31]. These observations lead us to
examine maIL-15 on DC and CD40L expression on CD4+ T cells.
Indeed, significant increase in malL-15 was found in group 3 (from
37.2%63.5 to 45.164.8, p = 0.024), but not in the other 3 groups
of macaques (Table 2A); representative flow cytometry illustration
is presented in Fig. S5A. Examination of CD4+ T cell showed
significant increases in CD40L expression only in group 3
macaques from 25.8(63.6) to 44.7(67.7) (p = 0.001) (Table 2B
and Fig. S5B). These results confirm in vivo that immunization with
the HLA constructs upregulates maIL-15 in DC and CD40L in
CD4+ T cells of macaques in the protected group 3.
Correlation between IL-15 and CD40L with A3G and AID
expression
MaIL-15 was examined in DC of the 5 groups and showed
significant direct correlation between IL-15 expression and A3G
mRNA in PBMC (p = 0.019), and the central memory T cells
(p = 0.041) at the time of challenge (Fig. 6A, D); these correlation
were however, not reflected in groups 1 and 3 animals (Fig. 6 B–F).
In contrast, IL-15 was correlated with A3G in the effector memory
T cells in the protected group 3 (p = 0.035; Fig. 6) but not in the
combined or group 1 animals (Fig. 6G, H). B cell analysis in all
animals also demonstrated a significant correlation between maIL-
15 of DC with A3G in CD20+CD27+ memory B cells (p = 0.043;
Fig. 6M), which was also seen in group 3 macaques (p = 0.031;
Fig. 6O), but not with A3G in CD20+ B cells.
Figure 3. A3G mRNA in PBMC and A3G protein in central and effector memory CD4+ T cells. A3G mRNA expression in PBMC (A), protein
in CD4+CD95+CCR7+ central (B) and CD4+CD95+CCR72 effector memory T cell subsets (C) and representative illustration (D) and (E) respectively, in 5
groups of macaques before and after immunization, assayed by RT-PCR for A3GmRNA and flow cytometry using MAb to CD4, CD95 and CCR7.
*p,0.05, **p,0.01. In all figures the 2 uninfected macaques in group 3 are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g003
Figure 4. Correlation between A3G memory B and CD4+ T cells, and A3G mRNA with HLA or neutralizing antibodies. Correlation
between A3G in CD20+CD27+ memory B cells and CD4+CD95+CCR72 effector memory T cells (A) in all 5 groups, (B) in group 1 (without SHIV antigens)
and (C) in group 3 macaques. Correlation between A3G mRNA in PBMC and serum anti-HLA class I antibodies (D–F), anti-HLA class II antibodies (MFI)
(G–I) assayed by the Luminex HLA antibody method and neutralizing activity (J–L) determined by using a TZM-b1 assay in the corresponding groups.
In all figures the 2 uninfected macaques in group 3 are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g004
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Further analysis revealed significant direct correlation between
CD40L in CD4+ T cells and A3G mRNA in PBMC (p = 0.034;
Fig. S4A), but not with the CD4+ memory T cells in the 5 groups
of animals (Fig. S4 B, C). Analysis of A3G and AID in CD20+ B
cells failed to show any correlation with CD40L+CD4+ T cells
(Fig. S4 D, F). However, A3G in CD20+ CD27+ memory B cells
was significantly correlated with CD40L in CD4+ T cells (p = 0.02,
Fig. S4E). Altogether, both maIL-15 in DC and CD40L in CD4+
T cells were directly correlated with A3G mRNA in PBMC,
suggesting that immunization with the HLA-SHIV vaccine elicited
the sequence of maIL-15RCD40LRA3G and this was most
significant in A3G mRNA and A3G protein in CD20+ CD27+
memory B cells in the protected group 3 animals.
Figure 5. Correlation between the viral load and A3G mRNA, protein in B cells or AID. Correlation between PVL or CVL and A3G mRNA in
PBMC (A,B), AID (C, D), A3G proteins in CD20+ B cells (E,F) and A3G in CD4+CD95+CCR72 effector memory T cells (G,H). AID and A3G were assayed
after the 4th immunization, whereas CVL was calculated as the ‘‘area under the curve’’. The two protected macaques are shown by open circles.
Pearson’s correlation coefficient was used for statistical analysis. In all figures the 2 uninfected macaques in group 3 are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g005
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Discussion
The major aims were to study the effect of immunization with
novel HLA class I and II constructs, linked in proximity on
dextran with trimeric HIV gp140, SIVgag p27 and HSP70, on
A3G and AID expression in circulating B cells and A3G in CD4+
T cells. The potential dual effect of upregulating AID and A3G in
B cells was explored by analyzing any association between them
and those of A3G in CD4+ T cells and the 3 major antibody
isotypes to the immunizing antigens. To enable evaluation of any
protective effect of A3G and AID, the macaques were challenged
with SHIV SF162.P4 and PVL and CVL were compared with
Table 2. Membrane-associated (ma) IL-15 of DC and CD40L expression of CD4+ T cells in 5 groups of macaques.
(A) maIL-15 in DC (B) CD40L in CD4+ T cells
Group Pre Post T p Pre Post t p
1 34.365.2 40.564.5 1.222 0.131 29.66(3.1) 32.1(5.0) 1.170 0.140
2 26.869 25.964.3 0.183 0.43 26.2(3.5) 25.3(2.5) 0.355 0.366
3 37.263.5 45.164.8 2.451 0.024 25.8(3.6) 44.4(7.7) 4.707 0.001
4 46.564.4 38.161.9 1.899 0.059 23.4(3.8) 19.3(3.6) 0.792 0.232
5 31.963.8 27.662.7 0.966 0.183 28.6(3.1) 24.9(3.9) 1.095 0.154
Anova F = 3.999, p = 0.009 F = 48.761, p,0.0001
(A) Membrane-associated (ma) IL-15 of DC and (B) CD40L expression on CD4+ T cells in 5 groups of macaques pre- and post-4th immunization, presented as % mean
(6sem). The significance between pre- and post-immunization was analysed by paired ‘‘t’’ test and differences between the 5 groups after immunization was analysed
by ANOVA.
doi:10.1371/journal.pone.0034433.t002
Figure 6. Correlation between DC maIL-15 and A3G mRNA or protein in CD4+ central and effector T or B memory cells. Correlation
between maIL-15 on DC and A3G mRNA in PBMC (A–C), intracellular A3G protein in CD4+CD95+CCR7+ central memory cells (D–F), CD4+CD95+CCR72
effector memory cells (G,I), CD20+ B cells (J–L) or CD20+CD27+ memory B cells (M–O) in the combined groups (1–5), group 1 or group 3 macaques,
respectively. IL-15 and A3G were assayed after the last immunization and before the animals were challenged with SHIV SF162.P4. In all figures the 2
uninfected macaques in group 3 are indicated by a solid circle.
doi:10.1371/journal.pone.0034433.g006
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A3G and AID expression between the immunized, unimmunized
and control macaques lacking either HLA constructs or SHIV
antigens.
Analysis of the entire cohort of 38 macaques clearly demon-
strated that A3G mRNA in PBMC is inversely correlated with
both the PVL and CVL (p,0.0001). Significant inverse correla-
tion was found between the CVL and A3G protein in CD20+ B
cells (p = 0.046) and the effector memory T cells
(CD4+CD95+CCR72, p = 0.01), but not CD4+ central memory
T cells. These results suggest that A3G may exert a significant
inhibitory effect on SHIV replication affecting the CVL and to a
lesser extent the PVL. This appears to be quantitatively more
significant in the CD4 effector memory T cells than CD20+CD27+
memory B cells. As B cells generally do not get infected by HIV or
SHIV but they release readily A3G containing exosomes [32], the
difference in expression of A3G between T and B cells may reflect
the direct anti-viral function of A3G in T cells and an indirect
effect exerted by B cells.
To evaluate A3G as a putative correlate of infection we
analysed macaques in group 3, which were immunized with the
whole vaccine (including HLA and HIV/SIV antigens, as well as
the Titermax adjuvant), and was the only group to demonstrate
either total protection or a significant decrease in viral load, as
reported recently [29]. This required both the HLA constructs and
SHIV antigens, as the previous studies with HLA immunization
have clearly demonstrated that immunization without HLA or
HIV/SIV antigens failed to elicit significant protection on
challenge with SHIVSF162.P4 [29]. Analysis of the immune
parameters in the 5 groups of macaques clearly indicate that
animals mostly in the protected group 3 showed significant
increase in A3G mRNA, though those in group1 (without HIV/
SIV antigens) also showed a small increase in A3G mRNA, which
was not significant. However, A3G in effector and central memory
T cells was significantly upregulated in all 4 immunized groups of
animals and the central memory T cells in groups 1, 2 and 4. In
contrast CD20+CD27+ memory B cells were increased only in
group 3. It was surprising that the CD27+ memory B cells
appeared to be more discriminating than the CD4+ memory T
cells, as the increase in A3G was confined to the protected group 3
animals. It is possible that the B cell contribution of A3G exosomes
to CD4+ T cells and other SHIV-permissive cells may tip the
balance in favour of A3G in countering the effect of vif.
Furthermore, a significant direct correlation between A3G
expressed in CD4+ effector memory T cells and CD27+ memory
B cells was also found only in group 3 macaques. It is noteworthy
that significant upregulation of A3G mRNA has been observed in
group 3 animals already after the first immunization (p = 0.003).
Altogether these results argue in favour of A3G produced both in
T and B cells contributing to an innate protective immunity
against SHIV infection.
The mechanism of the dual source of A3G is novel. For A3G
produced by B cells to prevent SHIV infection it must be
transmitted to CD4+ T cells, macrophages or DC. B cells are a
major source of exosomes [32] in which A3G is a major
component [33] which may confer virus restricted replication in
CD4+ recipient cells [34]. Thus, a most likely mechanism is that
A3G-rich exosomes from B cells will either directly or via
nanotubes produced by B cells contact CD4 T cells [35].
Exosomes rich in A3G may have contributed to preventing SHIV
infection in the passive transfer experiments [29], in which whole
serum was used and AID may have affected the antibody class and
affinity. Although B cells are not infected by HIV, an alternative
mechanism is to bind the virions through CD21 complement
binding receptor on B cells and transmit the virus to activated
CD4+ T cells [2]. A3G produced by B cells might inhibit this
process but this will need to be studied.
Nonetheless, immunization with the recombinant HLA con-
structs elicited only 25% prevention of SHIV infection, though the
remaining animals showed a h decrease in viral load, compared
with immunization with SIV inactivated whole CD4+ T cells,
which induced up to 90% protection [18–22]. These differences
are likely to be accounted for by greater immunogenicity of whole
cells with a multitude of antigen that included HLA A, B, C, DR,
DQ and DP, compared with the pure recombinant HLA antigens.
Furthermore, HLA of the immunizing CD4+ T cells/SIV was the
same as the challenge SIV (grown in the same cells), unlike the
immunizing recombinant HLA alleles, of which only 1 HLA
class I and 1 class II (DR) allele were the same as those in the
challenge SHIV. The dose of the candidate vaccine constituents
was not optimized, as the priority was to demonstrate immuno-
genicity and evidence of protection.
As both A3G and AID deaminases are produced in B cells and
HLA stimulation elicits both functions [28,36], we explored the
effect of HLA/SIV immunization on AID. A progressive increase
in significance of AID expression was observed after the 2nd
immunization from group 2 with HIV/SIV antigens (p = 0.043),
to group 1 with HLA antigens (p = 0.025) and group 3 with both
HIV/SIV and HLA antigens (p = 0.003). A parallel increase with
A3G was observed in the same samples of PBMC. This was
consistent with finding a very significant correlation between A3G
and AID in CD20+ B cells (p = 0.001), and the evidence that AID
is a member of the APOBEC family [12,37–39]. Howevever,
unlike A3G, AID appears to be restricted to the cytidine-
deaminase dependent activity. Indeed, a direct correlation was
found between A3G mRNA in B cells and anti-HLA–II antibodies
in the protected group 3 animals (p = 0.046). Furthermore, AID in
CD20+ B cells shows a trend that does not reach significance with
HLA-class II IgG antibodies (p = 0.11) as do IgG and IgA
antibodies to HIV gp120 (p = 0.10). These data suggest that
upregulation of AID [40], which is maximal on immunization with
the combined HLA-HIV/SIV vaccine candidate used in group 3,
stimulated the adaptive function of antibodies. An alternative
interpretation is based on the report that control of mouse Friend
Virus 3 (Rfv3) infection is associated with murine A3 encoded by
the Rfv3 gene, which influences control of the infection by
neutralizing antibodies [41]. AID in contrast to its manifestations
has not been studied in the context of immunization against micro-
organisms, so it is noteworthy that AID showed a significant
inverse correlation both with the peak and cumulative viral load.
Finally, we attempted to identify the cellular interactions
between DC, CD4+ T cells and B cells and the mechanism of
upregulation of A3G and AID. Activated CD4+ T cells express
cell-surface CD40L, which bind CD40 on DC, stimulating the
NF-kB transcription signaling pathway [31]. This activates
membrane associated IL-15/IL15Ra molecules, which in turn
bind the IL-15R complex on CD4+ T cells and reactivate the
memory circuit [31]. A parallel memory circuit ligating CD40
molecules on B cells is likely to be involved, but we have not
pursued it. CD40L-bound CD40 also activates ERK1/2 and p38
MAP kinase, inducing A3G mRNA, protein expression [27] and
AID[36]. IL-15 upregulates directly A3G in CD4+ T cells by
interacting with IL-15 receptor complex [28], which in turn
upregulates CD40L in CD4+ T cells and activates CD40
molecules expressed by B cells. CD40L in the presence of HLA
antibodies upregulate A3G and AID[36]. This is consistent with
group 3 and 1, the only groups in which HLA antigens and the
adjuvant were present, showing increase in maIL-15 DC and
CD40L in CD4+ T cells. Upregulation of maIL-15 among other c
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chain cytokines may also play a part in maintaining the
homeostatic proliferation and conversion of naı¨ve into memory
T cells [42]. This concept has been recently highlighted by
emphasis on IL-15 and IL-7 complementing weak triggering of the
T cell antigen receptors [43].
As most HIV-1 infections are transmitted at mucosal surfaces
(cervico-vaginal, rectal or penile), a dual protective immune
function may be carried out by B cells, upregulating AID early
after immunization, which activates CSR from IgM to IgG and
IgA antibodies, and SHM inducing affinity maturation. Thus, the
critical antibody functions expressed by AID might serve as a
combined surrogate of protection, which has so far not been
applied in vaccination studies. A3G elicits innate anti-viral activity
and AID adaptive immune responses, which may exert post- and
pre-entry anti-viral functions, respectively at the most vulnerable
mucosal sites of infection. Overall the data are consistent with the
hypothesis that HLA-SHIV immunization in macaques elicits
both a conventional adaptive response, as demonstrated by HLA
and HIV antibodies, and an innate A3G antiviral response. It is
likely that A3G is upregulated early after an encounter with the
virus and exerts a protective control over the virus, as the balance
between A3G and vif will be shifted in favor of A3G. An
alternative interpretation is that A3G might be of the LMM type,
which is vif independent [10]. Furthermore, HSP70 was a
component of the vaccine as it acts as a co-adjuvant and inhibits
replication [44] possibly by binding Vif and A3G, thereby
preventing Vif from ubiquitination and proteosomal degradation
of A3G [45] or providing an A3G shield [12]. The innate response
may control virus replication until an adequate antibody class,
affinity and concentration develop and prevent or inhibits the
infection. Antibodies may have been involved in anti-viral effect
either by neutralizing antibodies, ADCC (antibody dependent
cytotoxity [46], or by Fcc receptor-mediated antibody dependent
cellular virus inhibition [47]. The critical contribution of
antibodies in protection elicited by the vaccine construct has been
presented [29]. It should be noted however, that A3G may under
some experimental conditions and especially with low deaminase
activity promote mutation of the virus, which could affect its
virulence [48,49]. This possibility is unlikely in the present study,
as one of the 4 immunization groups were protected and the other
3 did not show an increase in viral load.
The mechanism of AID function in SHIV restriction is
dependent on its two constitutive functions, CSR and SHM.
The IgM-IgG-IgA switch has been demonstrated with HIVgp120
antibodies, as only significant IgM class of antibodies were found
after the 1st and only IgG and IgA antibodies after the last
immunization, consistent with class switch recombination. SHM is
inferred by the specific antibodies to both HLA-class I and II and
HIVgp120. Although the antibody titres were high, affinity was
not tested, so we are unable to say if affinity maturation has also
been elicited by SHM. Altogether, mostly IgG antibodies in the
systemic circulation and IgA as well as IgG antibodies in the
mucosal tissues will have exerted anti-viral effect. Further work is
needed to ascertain whether AID may function as a composite
marker of the level of antibody class, titre and affinity and whether
testing for AID is of greater significance than the sum of CSR and
SHM in the antiviral function.
The innate immune responses should contribute a significant
novel dimension to the known advantages of alloimmunization in
advancing a protective vaccine. The exposure to HLA class I or II
antigen elicits a rapid primary antibody response, which engages
the virus and is independent of viral mutation that may
subsequently take place. However, as both HLA and HIV
antigens were essential in eliciting protection with the recombinant
antigens [29], the contribution that each makes to the protective
mechanism will need to be elucidated. We suggest that the early
innate A3G anti-viral effect, combined with AID enhanced IgG
and IgA anti-HLA and SHIV antibody responses, offers an
alternative preventative immunization strategy against HIV
infection.
Materials and Methods
Ethics Statement
The study was carried out in compliance with the provisions
and general guidelines of the Swedish Animal Welfare Agency,
and all procedures were approved by the Ethical Committee on
Animal Experiments of North Stockholm (permit number N90/
06). Thirty-eight female rhesus macaques (Macaca mulatta) of
Chinese origin, 3–5 years old at the start of the study, were housed
in the Astrid Fagraeus laboratory at the Swedish Institute for
Infectious Disease Control. Housing and care procedures were in
compliance with the provisions and general guidelines of the
Swedish Animal Welfare Agency all procedures were approved by
the Local Ethical Committee on Animal Experiments. Immuni-
zations and blood sampling were performed under sedation with
ketamine 10 mg/kg intramuscularly (i.m.; Ketaminol 100 mg/ml,
Intervet, Sweden). Before entering the study, all animals were
confirmed to be negative for simian immunodeficiency virus (SIV),
simian T-cell lymphotropic virus and simian retrovirus type D.
The serum from a healthy AB+ blood donor as a source of
complement was acquired from Amsterdam, The Netherlands
Blood Bank.
Vaccine preparation
Four HLA class I alleles with the appropriate peptides were
selected: (1) HLA-A*01:01(IVDCLTEMY), (2) HLAA*02:01(-
GLIQLVEGV), (3) HLA-A*03:01(RIAAWMATY), (4) HLA-
A*11:01(VTDF SVIK) and one HLA class II allele HLA
DRB1*04:01; these will cover .90% of a Caucasian population.
The biotinylated vaccine components peptide-MHC class I and
class II complexes, trimeric HIVgp140, SIVp27 and HSP70359-609
were linked to streptavidin coated divinyl sulfone acid activated
dextran backbone [50].
Immunization and SHIV challenge of 5 groups of
macaques
The vaccines and immunization schedule has been reported
elsewhere [29]. Briefly, 4 groups of 8 and 1 group of 6 Chinese
rhesus macaques were immunized SC at 0, 4, 8 and 16 weeks:
group 1 animals received recombinant HLA class I and II, HSP70
and TiterMax adjuvant, group 2 had HIV gp120, SIV p27,
HSP70 and TiterMax group 3 had all vaccine components, HLA
class I and II, HIVgp120, SIVp27, HSP70 and TiterMax, group 4
had the same as group 3, but without the adjuvant (n = 6) and
group 5 was unimmunized (Table 1). The animals were challenged
IV with 18 MID50 of SHIVSF162P4 (kindly provided by Nancy
Miller at NIAID, NIH), propagated in the human T cell line
C8166-CCR5, which expresses HLA-A*01 and –DRB1*04. Viral
load was monitored as reverse transcriptase activity in plasma
using the 26 ExaVirH Load version 3 kit (Cavidi Tech AB,
Uppsala, Sweden) and translated to RNA equivalents/ml.
Real-time PCR for APOBEC3G mRNA in PBMC
Macaque PBMC (16106) were thawed from cryo-perserved
samples into RPMI 1640 medium supplemented with 10% FCS.
After centrifugation at 500 g for 5 min the cell pellets were washed
with PBS. RNA was isolated using a Total RNA Isolation Kit
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(Promega, Southampton,UK), quantified by spectrophotometry
(GeneQuant II, Pharmacia Biotech), and cDNA was generated
from RNA by using the Reverse Transcription System (Promega),
according to the manufacturer’s instructions. Relative amount of
A3G mRNA was quantified by real-time PCR (ABI Prism 5700)
using the Platinum SYBR green qPCR SuperMIX-UDG with
ROX (Invitrogen Life Technologies) as described before [15]. The
results were expressed as the copy number per ng of total RNA.
mRNA studies on isolated B and T cells were not possible, as the
yield of those cells was inadequate with the available number of
PBMC.
A3G and AID Protein Studies by Flow Cytometry
Intracellular A3G protein expression in CD4+ T cells, A3G and
AID in CD20+ B and the corresponding memory cells were
assayed by intracellular staining with anti-A3G Mab (Immuno-
Diagnostics Inc, Woburn MA) and rabbit anti-AID Ab (Abnova,
Caltagmedsystems, UK) in combination with cell surface staining.
The pre- and post-immunized samples were analysed in parallel in
each assay. The viability of thawed cells was checked by trypan
blue exclusion and was greater than 85%. Macaque CD4+ naı¨ve
cells were identified by CD95 low and memory cells by CD95 high
expression with antibodies to CD4 and CD95 (BD Biosciences,
Oxford). Central memory cells were identified as CCR7+ and
effector memory cells as CCR72 cells with anti-CCR7 antibodies
(R&D System, Oxford, UK), as described before [15]. B cells were
identified by antibodies to CD20 and memory B cells by CD27
(BD Biosciences, Oxford). After cell surface staining, the cells were
washed and fixed lightly with a fixation buffer containing
formaldehyde for 3 mins (eBioscience, Insight Biotechnology,
London UK), followed by treatment with the permeabilization
buffer (eBioscience). FITC labeled A3G mAb and rabbit anti-AID
were added to the samples followed by APC labeled sheep anti-
rabbit secondary antibody (ABDserotec Oxford) at 1:100 dilution.
The cells were analysed by flow cytometry on FACSCanto II (BD
Biosciences), using FACS Diva software. The pre-immunization
data in Fig. 1 and 2 are strictly not comparable, as those in Fig. 1
were stained for CD4 and A3G, whereas those in Fig. 2 were
stained not only for CD4 and A3G but also AID, The
reproducibility of AID and A3G assays in B cells were carried
out on 6 different samples of PBMC and repeated measures of
ANOVA showed no significant difference of either A3G (F = 0.23,
p = 0.8) or AID (F = 0.28, p = 0.78).
Flow cytometry analysis of IL-15 expression in DC and
CD40L expression in CD4+ T cells
Macaque DC were identified by incubating 16106 PBMC with
a cocktail of antibodies, showing high expression of HLA class II
and negative for CD14, CD20, CD3 and CD56 (BD Biosciences,
UK). IL-15 expression in the DC population was then analysed
with PE labeled anti-IL-1 Mab (R&D Systems, Oxford, UK). For
CD40L staining, 5 ml of FITC-conjugated mAb to CD40L or
isotype control antibody (BD Biosciences, BD Europe) was added
to 2x105 PBMC in 50 ml medium and were incubated for 5 hours.
After washing the cells were stained for CD4 and analysed by flow
cytometry.
Assays of serum antibodies to HLA class I and II and HIV
gp120
Serum HLA class I and class II antibodies were assayed using
the Luminex Labscreen mixed HLA antibody method (One
Lambda Inc., Canoga Park, CA). Labscreen single antigen beads
(One Lambda Inc.) was used to show the HLA antigen specificity.
The assays were carried out according to the manufacturer’s
instructions. Anti-HLA class I antibodies were assayed against
HLA A0101, A0201, A0301, A1101 and A2402 and anti HLA
class II antibody against DR0401 as described before [29].
Serum IgG, IgA and IgM antibodies to HIVgp120 were assayed
by ELISA (enzyme-linked immunosorbent assay) as described
previously (Yang et al., in preparation). Briefly, plates were coated
with a pre-determined optimal concentration of HIVgp120 (1 mg/
ml, NIBSC, Potters Bar, UK) and were then incubated with
double dilution of serum (starting dilution of 1:100). Bound
antibody was detected by incubation with rabbit IgG anti-monkey
IgA (8 mg/ml) (Nordic Immunological Laboratories, Tilberg, The
Netherlands), IgM or IgG antibodies (2 mg/ml; Sigma-Aldrich,
Poole, Dorset, UK), followed by affinity-purified goat anti-rabbit
IgG-alkaline phosphatase conjugate (Sigma). Antibody titres were
presented as O.D by calculating the area under curve for each
serum titration curve.
Neutralizing activity
Serum HIV neutralization activity was tested for inhibition of
SHIV-SF162.P4, replication in C8166-CCR5 cells (SHIV-
SF162.P4), using a TZM-bl based assay, as described previously
[29]. Neutralization activity in serum was analyzed both in the
presence of complement, using serum from a healthy AB+ blood
donor as a source of complement, and in the absence of
complement, using heat-inactivated AB+ serum. Briefly, SHIV
SF162.P4 was incubated in serial dilutions of macaque serum and
added to TZM-bl cells, luminescence was measured and the
percent neutralization was calculated by determining the reduc-
tion in luciferase expression in the presence of neutralizing agent
compared to the cultures with virus only. Fifty % inhibitory
dilutions (ID50) were determined by linear regression.
Statistical analysis
All results are expressed as mean (6sem). The paired Student’s t
test was used for analysis of significance between pre- and post-
immunized animals. Spearman rank or Pearson correlation
coefficient was applied for analysis of correlation. The total viral
load was calculated as the ‘‘area under the curve’’. The total anti-
HLA class I antibodies was calculated by adding up the MFI
values of 5 HLA class I antigen specific antibodies. The antibody
levels were presented as total OD values of each serum titre,
expressed as area under the curve [51]. Probability value (p),0.05
was considered to be significant.
Supporting Information
Figure S1 Correlation between AID and HLA-class I
antibodies in groups 1–4, 1 and 3. Correlation between AID
in CD20+ B cells and anti-HLA class I (A,C,E) or anti-HLA class
II antibodies (B, D, F); (A,B) in the immunized groups 1–4, (C,D)
in group 1 and (E,F) in group 3 macaques. In all figures the 2
uninfected macaques in group 3 are indicated by a solid circle.
(TIF)
Figure S2 Comparison of HIVgp120 antibodies and
correlation with AID in B cells. Comparison of serum HIV
gp120 specific IgM, IgG and IgA antibodies, in the 5 groups of
macaques after the 1st (A–C) and 4th (D–F) immunization;
correlation between AID in CD20+ B cells and HIVgp120 IgG
(G) or IgA (H) antibodies in all groups and in group 3 macaques
(I,J). The antibodies were measured by ELISA and expressed as
mean (6sem) of the OD (area under the curve). *p,0.05,
**p,0.01 and ***p,0.001 compared with the untreated group 5
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controls. In all figures the 2 uninfected macaques in group 3 are
indicated by a solid circle.
(TIF)
Figure S3 Indirect trend of correlation between the
viral load and A3G in memory B and T cells. Indirect trend
of correlation between the peak or cumulative viral load and A3G
in (A,B) CD20+CD27+ memory B cells and (C,D)
CD4+CD95+CCR7+ memory T cells. In all figures the 2
uninfected macaques in group 3 are indicated by a solid circle.
(TIF)
Figure S4 Correlation between CD40L and A3G mRNA
in PBMC or A3G in memory B and central T cells.
Correlation between CD4+ CD40L+ T cells and (A) A3G mRNA
in PBMC, (B) A3G protein in CD4+CD95+CCR7+ central, (C)
CD4+CD95+CCR7- effector memory T cells, (D) CD20+ B cells
and (E) CD20+CD27+ memory B cells. (F) Correlation between
CD40L and AID in CD20+ B cells in the 5 groups of animals. In
all figures the 2 uninfected macaques in group 3 are indicated by a
solid circle.
(TIF)
Figure S5 Rrepresentative flow cytometry of maIL-15
DC and CD40L expression of CD4+ T cells. Representative
flow cytometry illustrations are presented (A) for maIL-15 and (B)
CD40L; pre- (thin line) and post-immunization (bold line). In all
figures the 2 uninfected macaques in group 3 are indicated by a
solid circle.
(PPT)
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